Download PDF
Dtsch Med Wochenschr 2008; 133(25/26): 1366-1369
DOI: 10.1055/s-2008-1081082
Klinischer Fortschritt | Commentary

© Georg Thieme Verlag KG Stuttgart · New York

Hepatologie 2008

Hepatology 2008R. Thimme1 , H. C. Spangenberg1 , H. E. Blum1
  • 1Abteilung Innere Medizin II, Medizinische Universitätsklinik, Hugstetter Strasse 55, 79106 Freiburg
Further Information

Publication History

Publication Date:
13 June 2008 (online)

Also available at
    Permissions and Reprints

Was ist neu?

Virushepatitis:

  • Tenofovir bei Hepatitis B

  • Vakzineentwicklung bei Hepatitis C

  • chronischer Verlauf der Hepatitis E bei Transplantatempfängern

Alkoholhepatitis:

  • Neues prognostisches Modell

Leberzirrhose:

  • Transiente Elastographie zur Abgrenzung einer Fibrose

  • Norfloxacin zur Primärprophylaxe der spontan bakteriellen Peritonitis

Hepatozelluläres Karzinom:

  • Protektive Rolle von Östrogenen und Kaffee

  • Radiofrequenzthermoablation und Resektion bei kleinen Karzinomen gleichwertig

  • Cholangiozelluläres Karzinom

  • Hepatitis C, nicht-alkoholische und alkoholische Lebererkrankungen, Übergewicht und Rauchen als Risikofaktoren

Literatur

  • 1 Allen K J, Gurrin L C, Constantine C C. et al . Iron-overload-related disease in HFE hereditary hemochromatosis.  N Engl J Med. 2008;  358 221-230
    Google Scholar
  • 2 Bravi F, Bosetti C, Tavani A. et al . Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.  Hepatology. 2007;  46 430-435
    Google Scholar
  • 3 Cheng B Q, Jia C Q, Liu C T. et al . Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.  JAMA. 2008;  299 1669-1677
    Google Scholar
  • 4 Dalgard O, Bjoro K, Ring-Larsen H. et al . Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.  Hepatology. 2008;  47 35-42
    Google Scholar
  • 5 Fernandez J, Navasa M, Planas R. et al . Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.  Gastroenterology. 2007;  133 818-824
    Google Scholar
  • 6 Friedrich-Rust M, Ong M F, Martens S. et al . Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.  Gastroenterology. 2008;  134 960-974
    Google Scholar
  • 7 Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient.  N Engl J Med. 2008;  358 859-860
    Google Scholar
  • 8 Haagsma E B, van den Berg A P, Porte R J. et al . Chronic hepatitis E virus infection in liver transplant recipients.  Liver Transpl. 2008;  14 547-553
    Google Scholar
  • 9 Hui C K, Zhang H Y, Bowden S. et al . 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.  J Hepatol. 2008;  48 714-720
    Google Scholar
  • 10 Jacobson I M. Combination therapy for chronic hepatitis B: Ready for prime time?.  J Hepatol. 2008;  48 687-691
    Google Scholar
  • 11 Kamar N, Selves J, Mansuy J M. et al . Hepatitis E virus and chronic hepatitis in organ-transplant recipients.  N Engl J Med. 2008;  358 811-817
    Google Scholar
  • 12 Kim W R, Flamm S L, Di Bisceglie A M. et al . Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.  Hepatology. 2008;  47 1363-1370
    Google Scholar
  • 13 Kulik L M, Carr B I, Mulcahy M F. et al . Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.  Hepatology. 2008;  47 71-81
    Google Scholar
  • 14 Lai C L, Gane E, Liaw Y F. et al . Telbivudine versus lamivudine in patients with chronic hepatitis B.  N Engl J Med. 2007;  357 2576-2588
    Google Scholar
  • 15 Lai M, Hyatt B J, Nasser I. et al . The clinical significance of persistently normal ALT in chronic hepatitis B infection.  J Hepatol. 2007;  47 760-767
    Google Scholar
  • 16 Lampertico P, Vigano M, Manenti E. et al . Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.  Gastroenterology. 2007;  133 1445-1451
    Google Scholar
  • 17 Larsson S C, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis.  Gastroenterology. 2007;  132 1740-1745
    Google Scholar
  • 18 Law M, Maruyama T, Lewis J. et al . Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.  Nat Med. 2008;  14 25-27
    Google Scholar
  • 19 Lin C L, Liao L Y, Liu C J. et al . Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.  Hepatology. 2007;  45 1193-1198
    Google Scholar
  • 20 Livraghi T, Meloni F, Di Stasi M. et al . Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.  Hepatology. 2008;  47 82-89
    Google Scholar
  • 21 Llovet J, Rici S, Mazzaferro V. et al . Randomized phase III trial of sorafenib versus plazebo in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 LBA1
    Google Scholar
  • 22 Louvet A, Naveau S, Abdelnour M. et al . The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.  Hepatology. 2007;  45 1348-1354
    Google Scholar
  • 23 Mangia A, Minerva N, Bacca D. et al . Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.  Hepatology. 2008;  47 43-50
    Google Scholar
  • 24 McHutchison J G, Dusheiko G, Shiffman M L. et al . Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.  N Engl J Med. 2007;  357 2227-2236
    Google Scholar
  • 25 McMullan L K, Grakoui A, Evans M J. et al . Evidence for a functional RNA element in the hepatitis C virus core gene.  Proc Natl Acad Sci U S A. 2007;  104 2879-2884
    Google Scholar
  • 26 Naugler W E, Sakurai T, Kim S. et al . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.  Science. 2007;  317 121-124
    Google Scholar
  • 27 Pedersen I M, Cheng G, Wieland S. et al . Interferon modulation of cellular microRNAs as an antiviral mechanism.  Nature. 2007;  449 919-922
    Google Scholar
  • 28 Romero-Gomez M, Cordoba J, Jover R. et al . Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.  Hepatology. 2007;  45 879-885
    Google Scholar
  • 29 Sagir A, Erhardt A, Schmitt M. et al . Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.  Hepatology. 2008;  47 592-595
    Google Scholar
  • 30 Shaib Y H, El-Serag H B, Nooka A K. et al . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.  Am J Gastroenterol. 2007;  102 1016-1021
    Google Scholar
  • 31 Sung J J, Lai J Y, Zeuzem S. et al . Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.  J Hepatol. 2008;  48 728-735
    Google Scholar
  • 32 Tan J, Degertekin B, Wong S N. et al . Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.  J Hepatol. 2008;  48 391-398
    Google Scholar
  • 33 Thimme R, Spangenberg H C, Blum H E. Chronic hepatitis B.  Dtsch Med Wochenschr. 2008;  133 135-138
    Google Scholar
  • 34 Wedemeyer H, Cornberg M, Protzer U. et al . German guidelines on diagnosis and therapy of hepatitis B.  Dtsch Med Wochenschr. 2007;  132 1775-1782
    Google Scholar
  • 35 Welzel T M, Mellemkjaer L, Gloria G. et al . Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.  Int J Cancer. 2007;  120 638-641
    Google Scholar
  • 36 Yuen M F, Fong D Y, Wong D K. et al . Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.  Hepatology. 2007;  46 1695-1703
    Google Scholar

Prof. Dr. R. Thimme

Abteilung Innere Medizin II, Medizinische Universitätsklinik

Hugstetter Straße 55

79106 Freiburg

Email: robert.thimme@uniklinik-freiburg.de